M&A Deal Summary |
|
|---|---|
| Date | 2025-02-20 |
| Target | FibroGen China |
| Sector | Life Science |
| Buyer(s) | AstraZeneca |
| Sellers(s) | FibroGen |
| Deal Type | Divestiture |
| Deal Value | 160M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 54.1B USD (2024) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 22 |
| Sector: Life Science M&A | 19 of 20 |
| Type: Divestiture M&A Deals | 6 of 6 |
| Country: China M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 2 |
| Size (of disclosed) | 17 of 19 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-24 |
TRACERx
London, United Kingdom TRACERx is a tumor evolution study to generate deep sequencing multi-region and multi-time point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. TRACERx is based in London, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-03-17 |
EsoBiotec
Mont-Saint-Guibert, Belgium EsoBiotec is a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. By engineering immune cells directly within the patient’s body, the company is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases. Its proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology. EsoBiotec is based in Mont-Saint-Guibert, Belgium. |
Buy | $1.0B |
| Category | Company |
|---|---|
| Founded | 1993 |
| Sector | Life Science |
| Employees | 225 |
| Revenue | 30M USD (2024) |
FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen was founded in 1993 and is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: China M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
